Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal Membrane Oxygenation

ConditionsVV ECMO Bleeding Thrombosis Transfusion Adverse Reaction COVID-19

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorRigshospitalet, Denmark

About this trial

The investigators aim to assess the risk of bleeding and thrombo-embolic complications as well as benefit and harm of blood product transfusion and anticoagulation therapy in adult ICU patients with COVID-19 supported with V-V ECMO

Eligibility criteria

Qualifiers

Adults

Polymerase chain reaction (PCR) verified COVID-19 infection

Supported with V-V ECMO in this center

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

50 Participants

are grouped into 1 trial group

Sponsors and collaborators

Rigshospitalet, Denmark

Lead sponsor

Source ClinicalTrials.gov